Rachel Long1, Montana L Drawbaugh2, Charlene M Davis3, Charles R Goodlett2, Jane R Williams2, Randall J Roper4. 1. Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, IN, United States. 2. Department of Psychology, Indiana University-Purdue University Indianapolis, Indianapolis, IN, United States. 3. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States. 4. Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, IN, United States. Electronic address: rjroper@iupui.edu.
Abstract
OBJECTIVE: Usage of and views concerning alternative therapies in the DS community are not well documented. Some positive effects of green tea extracts (GTE) containing Epigallocathechin-3-gallate (EGCG) have been reported in individuals with DS and DS mouse models, but minimal improvements or detrimental effects of pure EGCG treatment have been reported in DS mouse models. Given the uncertainty about the effectiveness of these supplements, the goal of this study was to determine the relative prevalence of and attitudes about GTE/EGCG treatments among DS caregivers. METHODS: An anonymous survey about attitudes and usage of GTE/EGCG in individuals with DS was completed by caregivers of these individuals. RESULTS: GTE/EGCG treatment was provided by 18% of responding caregivers who were mostly younger, highly educated, and utilized scientific sources and other parents to influence their decision to use GTE/EGCG. Individuals with DS who received GTE/EGCG were characterized as less severely disabled. Most caregivers who did not give GTE/EGCG reported concerns about potential side effects and lack of effectiveness. Few caregivers consulted with medical providers about GTE/EGCG usage. CONCLUSIONS: These results demonstrate a need for communication between caregivers, medical providers, and scientists about potential benefits and risks for adverse effects of GTE, EGCG, and other nutritional supplements in individuals with DS.
OBJECTIVE: Usage of and views concerning alternative therapies in the DS community are not well documented. Some positive effects of green tea extracts (GTE) containing Epigallocathechin-3-gallate (EGCG) have been reported in individuals with DS and DS mouse models, but minimal improvements or detrimental effects of pure EGCG treatment have been reported in DS mouse models. Given the uncertainty about the effectiveness of these supplements, the goal of this study was to determine the relative prevalence of and attitudes about GTE/EGCG treatments among DS caregivers. METHODS: An anonymous survey about attitudes and usage of GTE/EGCG in individuals with DS was completed by caregivers of these individuals. RESULTS:GTE/EGCG treatment was provided by 18% of responding caregivers who were mostly younger, highly educated, and utilized scientific sources and other parents to influence their decision to use GTE/EGCG. Individuals with DS who received GTE/EGCG were characterized as less severely disabled. Most caregivers who did not give GTE/EGCG reported concerns about potential side effects and lack of effectiveness. Few caregivers consulted with medical providers about GTE/EGCG usage. CONCLUSIONS: These results demonstrate a need for communication between caregivers, medical providers, and scientists about potential benefits and risks for adverse effects of GTE, EGCG, and other nutritional supplements in individuals with DS.
Authors: Allison A Yates; John W Erdman; Andrew Shao; Laurie C Dolan; James C Griffiths Journal: Regul Toxicol Pharmacol Date: 2017-01-18 Impact factor: 3.271
Authors: Christina M Bauer; Miriam B Ishak; Emilie K Johnson; Jennifer L Beebe-Dimmer; Kathleen A Cooney Journal: Integr Cancer Ther Date: 2011-08-05 Impact factor: 3.279
Authors: Rafael de la Torre; Susana de Sola; Gimena Hernandez; Magí Farré; Jesus Pujol; Joan Rodriguez; Josep María Espadaler; Klaus Langohr; Aida Cuenca-Royo; Alessandro Principe; Laura Xicota; Nathalie Janel; Silvina Catuara-Solarz; Gonzalo Sanchez-Benavides; Henri Bléhaut; Iván Dueñas-Espín; Laura Del Hoyo; Bessy Benejam; Laura Blanco-Hinojo; Sebastiá Videla; Montserrat Fitó; Jean Maurice Delabar; Mara Dierssen Journal: Lancet Neurol Date: 2016-07 Impact factor: 44.182
Authors: Raza Jamal; Jonathan LaCombe; Roshni Patel; Matthew Blackwell; Jared R Thomas; Kourtney Sloan; Joseph M Wallace; Randall J Roper Journal: PLoS One Date: 2022-02-23 Impact factor: 3.752